MGI and AddLife AB: A Strategic Collaboration to Revolutionize Life Science in the Nordic Region

Jun 9, 2023

Feature 1

MGI and AddLife AB: A Strategic Collaboration to Revolutionize Life Science in the Nordic Region
MGI and AddLife AB: A Strategic Collaboration to Revolutionize Life Science in the Nordic Region

MGI and AddLife AB: A Strategic Collaboration to Revolutionize Life Science in the Nordic Region

Stockholm, Sweden, 8 June 2023 - MGI Tech Co. Ltd. ("MGI"), a global leader in life science technology, is thrilled to announce a strategic collaboration with AddLife AB, one of Europe's largest distributors of clinical testing and laboratory equipment. This partnership aims to significantly enhance the distribution of MGI's cutting-edge products* in the Nordic region, leveraging the expertise and market presence of AddLife AB's Triolab Group subsidiaries, and expanding into innovative fields such as point-of-care testing (POCT) and remote ultrasound.

The Power of Partnership: MGI and AddLife AB

Under the agreement, AddLife AB's four Triolab Group subsidiaries, namely Triolab Sweden, Triolab Norway, Triolab Denmark (Iceland), and Triolab Finland will serve as separate distributors for MGI's innovative products*. This partnership represents a significant milestone in the life science industry, combining the strengths of two industry leaders to meet the evolving needs of healthcare providers in the Nordic region.

A Shared Vision for Innovation and Excellence

"At AddLife, we aim to meet all our customers' needs at the highest level. Innovation is one of our core values and the addition of the product line from MGI is a perfect complement to our laboratory portfolio in that respect. It gives our customers the possibility to use the most modern and innovative technology.", Kai Rantanen, Head of the Diagnostic Business at AddLife AB said.

MGI's Commitment to Advancing Life Science

Duncan Yu, President of MGI, also shared his thoughts on the collaboration, stating, "We are thrilled to partner with AddLife AB and its Triolab Group subsidiaries to expand our reach in the Nordic region. The extensive distribution network and market expertise of AddLife AB, combined with MGI's leading-edge sequencing products*, will enable us to effectively meet the needs of healthcare professionals and contribute to improved patient outcomes.”

A Milestone in Healthcare Innovation

The collaboration between MGI and AddLife AB represents a significant milestone in responding to the evolving needs of healthcare providers in the Nordic region. By combining their respective strengths and expertise, both companies aim to accelerate the adoption of cutting-edge sequencing technologies and promote improved patient care across the region.

About AddLife

AddLife is an independent European provider in life science that offers high quality products, services and consulting to both the private and public sectors. AddLife has about 2,200 employees in around 85 operating subsidiaries, which operate under their own brands. The Group has annual sales of approximately SEK 9 billion. AddLife is listed on the Nasdaq Stockholm stock exchange.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

MGI TECH CO., LTD.

LIFE SCIENCE INNOVATION

ADDLIFE AB

GENE SEQUENCING

TRIOLAB GROUP

Share

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer
Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

Mar 4, 2024

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

MGI Tech has joined forces with Eurofins Genomics Europe Genotyping A/S, marking a pivotal moment in the advancement of large-scale genomic projects. This partnership heralds the first corporate order of the DNBSEQ-T20×2 ("T20") ultra-high throughput sequencer in Europe.

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding
Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

Nov 10, 2023

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

Latvia MGI Tech SIA advances DNA methylation research with significant European funding, achieving groundbreaking progress in biotechnology and innovation.

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment
MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

Jul 10, 2023

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

Explore MGI's latest achievement as its DNBSEQ-T20×2 gene sequencing platform wins the prestigious Globee® for Medical Equipment in the 15th Annual 2023 Golden Bridge Business and Innovation Awards®. This post highlights MGI's commitment to innovation in the life science industry, their groundbreaking T20 gene sequencer, and how their technology is reshaping healthcare outcomes and the genetic industry.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.